15.90

0.69% -0.13

After Hours: 15.87 -0.03 -0.19%

Anika Therapeutics Inc (ANIK)

Overview News Price History Option Chain Financials Discussions Forecast

Anika Therapeutics Inc stock is traded at $15.90, with a volume of 69,053. It is down -0.69% in the last 24 hours and up +9.94% over the past month. Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Previous Close:

$16.03

Open:

$16.19

24h Volume:

69,053

Relative Volume:

0.72

Market Cap:

$211.16M

Revenue:

$116.26M

Net Income/Loss:

$-11.08M

P/E Ratio:

-20.08

EPS:

-0.7917

Net Cash Flow:

$1.04M

1W Performance:

+8.82%

1M Performance:

+9.94%

6M Performance:

+61.79%

1Y Performance:

+47.27%

1-Day Range:

$15.74

$16.49

1-Week Range:

$14.70

$16.49

52-Week Range:

$7.8701

$16.49

Anika Therapeutics Inc Stock (ANIK) Company Profile

Name

Anika Therapeutics Inc

Sector

Healthcare (1100)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

(781) 457-9000

Address

32 WIGGINS AVENUE, BEDFORD, MA

Employee

235

Twitter

Next Earnings Date

2026-07-29

Latest SEC Filings

ANIK's Discussions on Twitter

Compare ANIK vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIK Anika Therapeutics Inc	15.87	213.29M	116.26M	-11.08M	1.04M	-0.7917
TAK Takeda Pharmaceutical Co Adr	16.96	53.37B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.84	42.80B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.65	41.09B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.29	31.62B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	563.70	23.23B	3.17B	1.29B	1.01B	27.09

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-25	Initiated	B. Riley Securities	Buy
Nov-01-24	Reiterated	Barrington Research	Outperform
Aug-14-23	Upgrade	Barrington Research	Mkt Perform → Outperform
Mar-07-23	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-09-22	Upgrade	Barrington Research	Mkt Perform → Outperform
Oct-14-22	Resumed	Stephens	Equal-Weight
Mar-09-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Mar-09-22	Downgrade	Stephens	Overweight → Equal-Weight
Nov-16-21	Initiated	Stephens	Overweight
Jul-16-21	Initiated	UBS	Neutral
Dec-16-20	Upgrade	Barrington Research	Mkt Perform → Outperform
May-08-20	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-21-20	Upgrade	Sidoti	Neutral → Buy
Jan-10-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Nov-05-19	Initiated	BWS Financial	Sell
Sep-24-19	Reiterated	Barrington Research	Outperform
Sep-23-19	Downgrade	First Analysis Sec	Strong Buy → Outperform
Jul-25-19	Upgrade	First Analysis Sec	Neutral → Strong Buy
Feb-22-19	Downgrade	First Analysis Sec	Outperform → Neutral
Feb-22-19	Downgrade	Sidoti	Buy → Neutral
Jul-27-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Jun-20-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-20-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
May-04-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Feb-23-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-24-18	Upgrade	First Analysis Sec	Equal-Weight → Overweight
Oct-27-17	Reiterated	Barrington Research	Outperform
May-09-16	Upgrade	Singular Research	BUY - Long-Term → Buy
Apr-27-16	Downgrade	Northland Capital	Outperform → Market Perform
Feb-26-16	Reiterated	Barrington Research	Outperform

View All

Anika Therapeutics Inc Stock (ANIK) Latest News

Jul 05, 2026

Price to book forward of Anika Therapeutics Inc. – NASDAQ:ANIK - TradingView

Jul 05, 2026

Jul 01, 2026

Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine - Traders Union

Jul 01, 2026

Jun 28, 2026

Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from Russell 2000 Value-Defensive Index - marketscreener.com

Jun 28, 2026

Anika Therapeutics, Inc.(NasdaqGS: ANIK) dropped from Russell 2000 Defensive Index - marketscreener.com

Jun 28, 2026

Jun 26, 2026

Early MRI scans uncover hidden risks in rotator cuff repair, Integrity Implant System data show - Traders Union

Jun 26, 2026

Anika Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANIK) - TradingView

Jun 26, 2026

Jun 25, 2026

ANIK Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Anika Therapeutics unveils Hyalofast cartilage repair scaffold using Hyaff hyaluronic acid technology - Traders Union

Jun 25, 2026

Jun 24, 2026

Behavioral Patterns of ANIK and Institutional Flows - Stock Traders Daily

Jun 24, 2026

Jun 23, 2026

Anika Shareholders Approve Directors and Expanded Incentive Plans - TipRanks

Jun 23, 2026

Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant - Stock Titan

Jun 23, 2026

Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares - Stock Titan

Jun 23, 2026

Anika Therapeutics (ANIK) director awarded 10,402 RSUs in stock grant - Stock Titan

Jun 23, 2026

[Form 4] Anika Therapeutics, Inc. Insider Trading Activity - Stock Titan

Jun 23, 2026

Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant - Stock Titan

Jun 23, 2026

Anika Therapeutics increases equity plan shares under amended omnibus and ESPP - TradingView

Jun 23, 2026

Anika Therapeutics (NASDAQ: ANIK) shareholders back equity plans and director slate - Stock Titan

Jun 23, 2026

Jun 22, 2026